Related Experiment Video
Updated: Jul 5, 2025
09:03
Field-Deployable Candidatus Liberibacter asiaticus Detection Using Recombinase Polymerase Amplification Combined with CRISPR-Cas12a
Published on: December 23, 2022
2.7K
CRISPR/Cas detection with nanodevices: moving deeper into liquid biopsy
Huimin Kong1, Ke Yi1, Rachel L Mintz2
1Laboratory of Biomaterials and Translational Medicine, Center for Nanomedicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China. limq567@mail.sysu.edu.cn.
Chemical Communications (Cambridge, England)
|January 22, 2024
Summary
CRISPR/Cas technology enhances liquid biopsies for precision diagnostics. Nanotechnology integration with CRISPR/Cas systems shows promise for disease detection, though challenges like off-target effects require further research.
Area of Science:
- Biotechnology
- Molecular Diagnostics
- Nanomedicine
Background:
- Liquid biopsy offers non-invasive real-time diagnostic data from bodily fluids.
- CRISPR/Cas technology provides precision and accuracy for advanced diagnostics.
- Nanotechnology integration is crucial for enhancing CRISPR/Cas applications.
Purpose of the Study:
- To review the merits and applications of CRISPR/Cas systems in liquid biopsy.
- To explore the role of nanodevices in improving CRISPR/Cas-mediated liquid biopsy.
- To identify challenges and potential solutions for CRISPR/Cas liquid biopsy adoption.
Main Methods:
- Literature review of CRISPR/Cas systems and nanotechnology in liquid biopsy.
- Analysis of current applications in disease diagnosis.
- Discussion of ongoing efforts in nanodevice design for enhanced sensing.
Main Results:
- CRISPR/Cas systems significantly advance liquid biopsy precision.
- CRISPR/Cas-mediated nanodevices demonstrate vast potential for precise diagnostics.
- Challenges include off-target effects and platform limitations.
Conclusions:
- CRISPR/Cas technology combined with nanodevices holds great promise for precision medicine.
- Further research is needed to overcome obstacles and enhance specificity and sensitivity.
- Nanoscale devices are key to improving CRISPR/Cas-based liquid biopsy performance.
